Another agent, NG-641, an oncolytic viral vector encoding an anti–LILRB2 antibody, is in early-phase clinical trials for patients with solid tumors, including NSCLC and colorectal cancer. This evidence concerns the gene LILRB2 and non-small cell lung carcinoma.